[
  {
    "ts": null,
    "headline": "Sanofi Edges Higher As Immunology Powerhouse, Dupixent, Wallops Forecasts",
    "summary": "Sanofi stock edged higher Thursday after its immunological powerhouse, Dupixent, handily beat Wall Street's fourth-quarter expectations.",
    "url": "https://finnhub.io/api/news?id=6233072b10a2ae9f800f87ff1bc397cc5997a752c9545bac6f76285681d9a734",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769706487,
      "headline": "Sanofi Edges Higher As Immunology Powerhouse, Dupixent, Wallops Forecasts",
      "id": 138297314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Sanofi stock edged higher Thursday after its immunological powerhouse, Dupixent, handily beat Wall Street's fourth-quarter expectations.",
      "url": "https://finnhub.io/api/news?id=6233072b10a2ae9f800f87ff1bc397cc5997a752c9545bac6f76285681d9a734"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026",
    "summary": "SNY tops Q4 earnings estimates, as Dupixent surges. It guides faster profit growth than sales in 2026, even as revenues narrowly miss",
    "url": "https://finnhub.io/api/news?id=d58f9ebd2a7b4ad0184bee92f87681de776ba2035315d27fc2fd15c9b5703498",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769703660,
      "headline": "Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026",
      "id": 138297315,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "SNY tops Q4 earnings estimates, as Dupixent surges. It guides faster profit growth than sales in 2026, even as revenues narrowly miss",
      "url": "https://finnhub.io/api/news?id=d58f9ebd2a7b4ad0184bee92f87681de776ba2035315d27fc2fd15c9b5703498"
    }
  },
  {
    "ts": null,
    "headline": "Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status",
    "summary": "BIIB secures FDA's Breakthrough Therapy status for litifilimab in cutaneous lupus, backed by phase II results, while advancing phase III and broader lupus studies.",
    "url": "https://finnhub.io/api/news?id=adbff8e3a0d7f09ed8f34052777bbfd9655f0ef59978cdc24432c3e9dd847204",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769694780,
      "headline": "Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status",
      "id": 138295940,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "BIIB secures FDA's Breakthrough Therapy status for litifilimab in cutaneous lupus, backed by phase II results, while advancing phase III and broader lupus studies.",
      "url": "https://finnhub.io/api/news?id=adbff8e3a0d7f09ed8f34052777bbfd9655f0ef59978cdc24432c3e9dd847204"
    }
  },
  {
    "ts": null,
    "headline": "Evercore ISI Highlights Dupixent and Eylea HD as Key Growth Drivers For Regeneron Pharmaceuticals, Inc. (REGN)",
    "summary": "We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. Regeneron Pharmaceuticals, Inc. is among the most profitable stocks. TheFly reported on January 22 that Evercore ISI increased its price target for REGN to $875 from $750 and maintained an Outperform rating on the stock. The firm expressed confidence […]",
    "url": "https://finnhub.io/api/news?id=39a46af6f0ac47995f22a9371d8d7da49b67971691734663f98d34a9f76945ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769692891,
      "headline": "Evercore ISI Highlights Dupixent and Eylea HD as Key Growth Drivers For Regeneron Pharmaceuticals, Inc. (REGN)",
      "id": 138294807,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. Regeneron Pharmaceuticals, Inc. is among the most profitable stocks. TheFly reported on January 22 that Evercore ISI increased its price target for REGN to $875 from $750 and maintained an Outperform rating on the stock. The firm expressed confidence […]",
      "url": "https://finnhub.io/api/news?id=39a46af6f0ac47995f22a9371d8d7da49b67971691734663f98d34a9f76945ae"
    }
  },
  {
    "ts": null,
    "headline": "PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything",
    "summary": "Healthcare is supposed to be defensive. When tech stocks swing wildly and consumer spending wobbles, healthcare companies keep selling drugs, performing surgeries, and processing insurance claims. That steady demand makes the sector attractive when investors want growth without the full roller coaster. But what if you could get healthcare exposure with a more concentrated bet ... PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything",
    "url": "https://finnhub.io/api/news?id=5ecd5f9a237559d9f1975a5686f05a175bfbd9f6aab58b80213020a4c2eac9c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769692834,
      "headline": "PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything",
      "id": 138295586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Healthcare is supposed to be defensive. When tech stocks swing wildly and consumer spending wobbles, healthcare companies keep selling drugs, performing surgeries, and processing insurance claims. That steady demand makes the sector attractive when investors want growth without the full roller coaster. But what if you could get healthcare exposure with a more concentrated bet ... PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything",
      "url": "https://finnhub.io/api/news?id=5ecd5f9a237559d9f1975a5686f05a175bfbd9f6aab58b80213020a4c2eac9c2"
    }
  },
  {
    "ts": null,
    "headline": "Apple, Oil Earnings, Inflation Data: Still to Come This Week",
    "summary": "Another huge technology company, Apple, is set to post quarterly earnings after results from Tesla, Microsoft and Meta Platforms. Plus, a reading on supplier inflation is due. Here is what to watch: Today ...",
    "url": "https://finnhub.io/api/news?id=84b822124cc11e99e7d6b6f143448b4ca73c6a7acab95c8642e242785e9dddb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769676878,
      "headline": "Apple, Oil Earnings, Inflation Data: Still to Come This Week",
      "id": 138293727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Another huge technology company, Apple, is set to post quarterly earnings after results from Tesla, Microsoft and Meta Platforms. Plus, a reading on supplier inflation is due. Here is what to watch: Today ...",
      "url": "https://finnhub.io/api/news?id=84b822124cc11e99e7d6b6f143448b4ca73c6a7acab95c8642e242785e9dddb7"
    }
  },
  {
    "ts": null,
    "headline": "Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg",
    "summary": "REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related to Alvotech’s biosimilar to Eylea® 2mg (aflibercept 40 mg/mL solution), which is approved for marketing in the European Economic Area, United Kingdom a",
    "url": "https://finnhub.io/api/news?id=f50fcf7acf54a0dd44a3c39e0201a8ee2165e144684dbe71808f81f1806f8e69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769673600,
      "headline": "Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg",
      "id": 138293203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related to Alvotech’s biosimilar to Eylea® 2mg (aflibercept 40 mg/mL solution), which is approved for marketing in the European Economic Area, United Kingdom a",
      "url": "https://finnhub.io/api/news?id=f50fcf7acf54a0dd44a3c39e0201a8ee2165e144684dbe71808f81f1806f8e69"
    }
  },
  {
    "ts": null,
    "headline": "Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.",
    "url": "https://finnhub.io/api/news?id=4ed6ee469b37a1cf1dd56fad5ba9961ab4542558cd6119b3c7d0194e0ee965ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769655808,
      "headline": "Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow",
      "id": 138291616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.",
      "url": "https://finnhub.io/api/news?id=4ed6ee469b37a1cf1dd56fad5ba9961ab4542558cd6119b3c7d0194e0ee965ad"
    }
  }
]